



# MARKET RELEASE

30 January 2018

**SIRTEX MEDICAL LIMITED**

**TRADING HALT**

The securities of Sirtex Medical Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 1 February 2018 or when the announcement is released to the market.

Security Code:               SRX

Kimberley Brown  
**PRINCIPAL ADVISER, LISTINGS COMPLIANCE (SYDNEY)**



Sirtex Medical Ltd  
ABN 35 078 166 122  
Level 33  
101 Miller Street  
North Sydney, 2060  
Phone +61 2 9964 8420  
[www.sirtex.com](http://www.sirtex.com)

30<sup>th</sup> January 2018

Kimberley Brown  
Senior Advisor, Listings  
ASX Limited  
Exchange Centre  
Level 6, 20 Bridge Street  
Sydney, NSW, 2000

**BY EMAIL:** [kimberley.brown@asx.com.au](mailto:kimberley.brown@asx.com.au); [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

Dear Kimberley

**Trading Halt Request**

In accordance with ASX Listing Rule 17.1, Sirtex Medical Limited (**Company**) requests an immediate trading halt in the shares of the Company.

The trading halt is requested pending an announcement to be made by the Company in relation to a potential material corporate transaction.

The Company requests that the trading halt remain in place until the earlier of an announcement to the market or the commencement of normal trading on Thursday, 1<sup>st</sup> February 2018.

The Company is not aware of any reason why the trading halt should not be granted, nor is it aware of any other information necessary to inform the market about the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read "Darren Smith", with a long horizontal flourish extending to the right.

**Darren Smith**  
**Chief Financial Officer and Company Secretary**  
**Sirtex Medical Limited**